Ann: Updated SNT-5505 study data to be presented at EHA2025, page-2

NZT
Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to
announce that its abstract has been selected for a poster presentation at the European
Hematology Association 2025 Congress (EHA2025).
The presentation will contain the next
data update from the ongoing Phase 2 trial evaluating SNT-5505 in combination with
ruxolitinib to treat the bone marrow cancer myelofibrosis.

Syntara’s abstract, titled ‘A PHASE 1/2A TRIAL OF PXS-5505, A NOVEL PAN-LYSYL OXIDASE
INHIBITOR, IN PATIENTS WITH ADVANCED MYELOFIBROSIS’, will be presented in Poster
Session 2 at 18:30 – 19:30 CEST, Saturday 14 June (02:30 – 03:30 AEST, Sunday 15 June).
The 30th EHA Congress is being held in Milan, Italy from 12-15 June 2025, and is a highly
regarded forum for original data, haematological innovation and evidence-based
knowledge of primary clinical relevance.

Syntara CEO Gary Phillips said: "We’re proud to see SNT-5505 selected for a poster
presentation at one of the premier haematology events worldwide in the EHA2025
Congress. This highlights the growing recognition of the potential impact of this program,
following strong early data presented at ASH2024. The timing of the conference aligns
well with the company receiving a substantial amount of additional data from the
ongoing myelofibrosis trial and facilitates peer review by the world’s leading
haematologists. We look forward to bringing the update to shareholders at the same
time.”

It should be noted that while abstracts for the EHA2025
Congress will be published on 14 May 2025,
the abstract relevant to Syntara’s SNT-5505 will only describe the study and will
not contain the new data. The new data will only be presented at the time of the event,
while being announced to the ASX within its continuous disclosure obligations.